Heron Therapeutics (HRTX) Receivables - Other (2020 - 2025)

Heron Therapeutics has reported Receivables - Other for 6 years, with the latest figure at $344000.0 in Q4 2025.

• For the quarter ending Q4 2025, Receivables - Other rose 30.8% year-over-year to $344000.0; the trailing twelve-month figure through Dec 2025 stood at $344000.0 (up 30.8% YoY), and the FY2025 full-year result was $344000.0, up 30.8% from the prior year.
• Receivables - Other for Q4 2025 stood at $344000.0, up from $263000.0 in the prior quarter.
• The five-year high for Receivables - Other was $6.2 million in Q4 2022, with the low at $103000.0 in Q4 2021.
• Historically, Receivables - Other has averaged $1.4 million across 5 years, with a median of $310000.0 in 2023.
• Annual changes were most pronounced in 2022 — Receivables - Other soared 5916.5% — and 2023, when it sank 95.0%.
• Heron Therapeutics' Receivables - Other stood at $103000.0 in 2021, then soared by 5916.5% to $6.2 million in 2022, then slumped by 95.0% to $310000.0 in 2023, then retreated by 15.16% to $263000.0 in 2024, then surged by 30.8% to $344000.0 in 2025.
• The last three Receivables - Other figures came in at $344000.0 (Q4 2025), $263000.0 (Q4 2024), and $310000.0 (Q4 2023), per Business Quant data.